OBESITY

Öz

Obesity has been defined as excess of body fat mass. In recent years, there is an increased prevelance of obesity in developed countries due to alteration of nutrition and lifestyle and economic spaciousness. It is showed that prevalence of obesity has also been increasing in growing countries as our country. Increase of obesity frequence is important because of accompanying with related problems (metabolic, endocrin,structural etc). Therefore, we studied to expose development, prevention and treatment of obesity in this review.

Anahtar Kelimeler

• Obesity

OBEZİTE

Öz

Obezite vücuttaki yağ miktarının fazlalığı olarak tanımlanmaktadır. Son yıllarda gelişmiş ülkelerde beslenme, yaşam biçiminin değişimi ve ekonomik ferahlık nedeniyle obezite prevelansında bir artış mevcuttur. Bizim gibi gelişmekte olan ülkelerde de prevelansın yüksek olduğu yapılan çalışmalarla gösterilmiştir. Obezitenin sıklığındaki artış; ilgili sorunları da ( metabolik, endokrin, yapısal gibi..) beraberinde getirdiğinden önemlidir. Bu yüzden obezitenin gelişimi, önlenmesi ve tedavisini bu derlemeyle ortaya koymaya çalıştık.

Anahtar Kelimeler

• Obezite

Kaynakça

1. [1] Kabalak T., “Endokrinoloji El Kitabı 4. Basım”, Kabalak T, Yılmaz C, Tüzün M, İzmir, 759-780 (2004).
2. [2] WHO. “Obesity: Preventing and Managing the Global Epidemic: report of a WHO Consultation on Obesity”, Geneva. World Health Organization. (1997).
3. [3] Jeffrey S.Flier. “Harrison’s Principles of İnternal Medicine 15 TH Edition”, McGraw Hill, Braunwald E., Fauci AS., Kasper DL., Hauser SL., Longo DL., Jameson JL., New York, 479 (2001).
4. [4] Legato MJ., “Gender-specific aspects of obesity”, Int J Fertil Womens Med. 42:184-197 (1997).
5. [5] Bouchard C., “Can obesity be prevented?” Nutr Rev. 54 (4 Pt 2):125-130 (1996).
6. [6] Caterson ID., Brom J., “Pocket Picture Guide Obesity 1th edition”, 20-47 (2001).
7. [7] Posıtıon Statement On The Preventıon, Dıagnosıs, And Treatment Of Obesıty. American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE)., http://www.aace.com/clin/guidelines/obesityguide.p Obesity Task Force and reports in the scientific literature as of February (1998).
8. [8] Field AE, Barnoya J, Colditz GA, “Handbook of Obesity Treatment 1th edition”, Wadden TA, Stunkard AJ, The Guilford Press, P:12-13 (2003).

9. [9] Wolf G, Sheldon C, Dong CH, Fuad NZ. “Leptin and renal disease”, American Journal of Kidney Diseases, Vol 39, No 1, 1-11 (2002).
10. [10] Funahashi H, Yada T, Suzuki R, Shioda S. “Distribution, function, and properties of leptin receptors in the brain”, Int Rev Cytol, 224:1-27 (2003).
11. [11] Onat A. “Türkiye'de Obezitenin Kardiyovasküler Hastalıklara Etkisi”, Türk Türk Kardiyoloji Derneği Arşivi, 31(5):279-289 (2003).
12. [12] Leisha Bevoni, PA-C, “MMSc .Management of Adult Obesity”, Clinician Reviews ® www.medscape.com (2003).
13. [13] Jeb SA., “Clinical Obesity 1th edition”, Blackwel Science Limited, Kopelman PG, Stock MJ, P: 30-33 (1998).
14. [14] Orhan Y. “Endokrinoloji, Metabolizma ve Beslenme Hastalıkları”, Editör : Sencer E., 716-733 (2001).
15. [15] National Heart, Lung, and Blood Institute Obesity Education Initiative. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults Available at: www.nhlbi .nih.gov/about/oei/index.htm. Accessed May 1, (2003).
16. [16] National Institute for Clinical Excellence. Surgery to aid weight reduction for people with morbid obesity: final appraisal determination. www.nice.org.uk/article.asp?a=32081 Accessed 12 Jul (2002).
17. [17] George A Bray, “Drug Terapy of Obesity”, Uptotade by April (2005).
18. [18] Mc Donald SP, Maguire GP, Duarte N, Wang XL, Hoy WE. “C reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community”. Cli Sci (Lond). ( Epub ahead of print) Sep 4 (2003).